drugset / Trial / NCT04136444
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.
Timeline
- Start
- 2019-10-28
- Primary completion
- 2020-05-22
- Completion
- 2020-05-22
Outcome
Outcome not reported
Stopped: “Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Padsevonil | Small molecule | — | — |
Indications
No indication recorded.